General Structure and Function
Secretin and its receptor hold special places in history, with secretin representing the first "hormone", giving rise to the field of endocrinology when W. M. Bayliss and E. H. Starling recognized it as a blood-borne non-neural mediator of pancreatic exocrine secretion in 1902 (1) , and with the secretin receptor cloned by T. Ishihara et al. in 1991 (2) , representing the first family B G protein-coupled receptor and giving rise to this new and important receptor family.
The secretin receptor is a guanine nucleotidebinding protein (G protein)-coupled receptor (GPCR) that binds to and is activated by the peptide hormone, secretin. This receptor was the first member of the B family of GPCRs (3, 4) , which also includes receptors for vasoactive intestinal polypeptide (VIP), pituitary adenylate cyclase-activating peptide (PACAP), glucagon, glucagon-like peptide (GLP), glucose-dependent insulinotropic polypeptide (GIP), calcitonin, calcitonin-like peptide, parathyroid hormone (PTH), corticotrophin-releasing factor (CRF), and growth hormone releasing hormone (GHRH) (3, 4) . It is notable that these receptors lack the classical signature sequences found in most members of the much larger A family of GPCRs (5, 6) . The most typical features of B family GPCRs includes a long amino-terminal tail region with six highly conserved cysteine residues that contribute to three structurally and functionally important intra-domain disulfide bonds, and seven hydrophobic transmembrane segments having residue conservation quite distinct from other family GPCRs (Fig. 1 , left panel) (5) (6) (7) .
In evaluation of these sequences, it has been proposed that the helical bundle of family B GPCRs is structurally distinct from that of family A GPCRs (5-7), even though it still likely includes a heptahelical bundle conformation and is known to couple with the same group of heterotrimeric G proteins. It is noteworthy that family B GPCRs typically couple with both Gs and Gq, in contrast to family A GPCRs that often couple with only a single dominant G protein. The extracellular amino-terminal tail domains of several members of this receptor family have recently been structurally characterized, either by NMR or crystallography, to exhibit a highly conserved core that includes two anti-parallel β-sheets, three disulfide bonds, and variable amino-terminal α-helix and multiple loop regions (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . The structure also provides a conserved hydrophobic peptide-binding cleft above the stable core and between the helix and loop regions.
Like many GPCRs, the secretin receptor is glycosylated on ectodomains, predominantly within the amino-terminal tail, and also on the second extracellular loop (18) .
These all represent sites of N-linked glycosylation of asparagine residues. Site-directed mutagenesis has demonstrated potential functional importance of glycosylation on Asn 72 and Asn 291 of the human secretin receptor (Fig 1 shows Asn78 and Asn263 of the rat sequence), representing the first of three glycosylation sites within the amino-terminal tail and the glycosylation site within the second extracellular loop, although selective, single mutation of the other sites had no demonstrable functional impact (18) .
Generally, the glycosylation sites of membrane receptors are important for proper folding during biosynthesis, ensuring normal trafficking, and for protecting the receptor from proteolytic degradation.
Desensitization of GPCRs often can be induced both by biochemical modifications such as phosphorylation and by cellular mechanisms such as internalization. The secretin receptor utilizes both of these. Like many receptors that activate intracellular kinases, phosphorylation of the secretin receptor is utilized as a biochemical mechanism for feedback regulation involved in desensitization.
Direct evidence for agoniststimulated phosphorylation of the secretin receptor was first demonstrated by Ozcelebi et al. (19) . That work established the phosphorylation of threonine and serine residues within the receptor carboxyl-terminal tail region. The kinases involved in phosphorylation of the secretin receptor were found to represent predominantly G protein-coupled receptor kinases, with minor action by both protein kinase A and protein kinase C (20) . Secretin receptor phosphorylation has been shown to disrupt G protein coupling (21) , but not to be necessary for agonist-induced receptor internalization (21) . The latter certainly occurs, and represents a major mechanism for desensitization of this receptor.
In recent years, it has been recognized that certain GPCRs can associate with themselves and with structurally related GPCRs to form oligomeric or dimeric complexes (22) . While most of these studies have been directed toward family C or family A GPCRs, recent work has shown that it is relevant to family B GPCRs as well (22) . The evidence is best for family C GPCRs, where dimeric structures typically have profound effects on receptor function and specificity, and where crystal structures of covalently-bonded dimeric complexes of ectodomains have been reported (23) . In family A GPCRs, there have been no consistent observations of which receptors might associate with themselves or other GPCRs, of functional effects of oligomerization, or of the impact of ligand binding on receptor oligomerization (23) . The secretin receptor is among the best studied family B GPCR in regard to its oligomerization. It is constitutively present within homo-dimeric complexes determined by the lipid-exposed face of the fourth transmembrane segment (24) (25) (26) .
This structure is critically important for achieving the high affinity G proteincoupled state of this receptor, with non-dimerizing mutants coupling less efficiently, binding secretin with lower affinity, and having less potent effects of secretin to stimulate cAMP (24) (25) (26) . Of note, only the dimeric state of this receptor exhibits negative cooperativity (24) , another protective feature of some receptor systems.
The structurally specific nature of secretin receptor homo-dimers appears to be consistent throughout this receptor family (27) . This receptor is also able to form hetero-dimers with other family B GPCRs (28) .
There is also a single report to demonstrate the ability of the single transmembrane Receptor Activity-Modifying Protein-3 (RAMP-3) to associate with the secretin receptor during its biosynthesis (29) . Of note, since the secretin receptor is able to traffick to the cell surface independent of its association with RAMPs, it is difficult to identify a specific effect of this bimolecular association, unlike those members of the B family of GPCRs that cannot get to the cell surface without RAMPs, such as the calcitonin receptor-like receptor (30) . Indeed, no specific functional effect has yet been demonstrated for RAMP-3 association with the secretin receptor (29) .
Like secretin, all of the natural ligands of family B GPCRs, represent moderately long peptide hormones having diffuse pharmacophoric domains (3, 4) . These all have the propensity to form helical structures, particularly in their carboxyl-terminal ends, a region of these peptides now known to bind to the hydrophobic cleft within the amino terminus of their receptors. This binding directs the amino-terminal region of these ligands toward the core helical bundle domain of their receptors. This portion of secretin and other family B GPCR ligands is responsible for its biological activity, with amino-terminally truncated forms of these ligands acting as antagonists (31) (32) (33) . The right panel of Figure 1 illustrates the current working model of secretin occupation of its binding site within the secretin receptor.
The classical effects of secretin are the stimulation of the secretion of bicarbonate, water, and electrolytes from the pancreatic ductular system, as well as the biliary ducts (34, 35) . These effects are largely stimulated by secretin released from S cells in the proximal intestine in response to intraluminal acid and fatty acids, thus playing a hormonal regulatory role and a classical feedback loop (35) . Subsequently, it has become clear that this receptor is also expressed in many other tissues, and that it has pleiotrophic roles (36). Of particular interest, some of these roles are mediated by neuronal secretin, thus acting as a neurotransmitter (37) . Many of the secretin receptors in brain and kidney play important roles related to fluid homeostasis (38) . Prominent expression in brain has been described in cerebellum, with intermediate levels of expression in cortex, thalamus, striatum, hippocampus and hypothalamus, and low levels of expression in midbrain, medulla, and pons (36, 39) . Secretin has been described to stimulate drinking behavior via central nervous system actions that include release of vasopressin (38, 40) . Secretin receptors are expressed on essentially all cells within the kidney, with this hormone described to stimulate renal blood flow and glomerular filtration rate, as well as tubular water reabsorption, and to have effects on translocation of aquaporin (38, 40) . Secretin has been described to have both diuretic and anti-diuretic effects, dependent on dose and route of administration (41) . Secretin receptors are also expressed on gastrointestinal smooth muscle, neurons, and certain mucosal cells, heart, and lung (39).
Like most family B GPCRs, the secretin receptor is known to couple to both Gs and Gq, with the cAMP response to stimulation most prominent and sensitive, while the intracellular calcium responses are only observed with high concentrations of hormone (42) . The determinants for G protein coupling have been best studied for family A GPCRs, where distinct motifs have been present in the juxtamembranous regions of the second and third intracellular loops and carboxyl-terminal tail (43, 44) . Some work has been reported for family B GPCRs (45) (46) (47) , but the same motifs in the same positions appear to be absent.
It is interesting that the determinants for coupling with these two G proteins are apparently both shared and distinct, with mutations able to disrupt both Gs and Gq coupling, as well as more selective disruption of some receptor mutations (47) .
Like many GPCRs, full signaling responses are recorded with less than 20 percent of receptors occupied (48, 49) . There are typically spare receptors present on physiologic targets of this hormone, but there have been no detrimental effects observed for stimulation with supramaximal concentrations of secretin.
These signaling pathways have prominent effects on cell surface transporters involved in fluid and electrolyte transport (38) . Stimulation of this receptor has also been observed to affect translocation and activation of various aquaporins in different tissues, consistent with its important roles in fluid homeostasis (38, 40) . While secretin receptors have been reported to be present on various neoplasms, including ductular carcinomas of the pancreas and selected islet cell carcinomas (50), it is not clear that the integrity of the receptor or the signaling responses to secretin are normal in those cells. In fact, the splicing of the secretin receptor mRNA has been reported to be abnormal in some of these tumors (51) (52) (53) (54) (55) . A series of secretin receptor spliceoforms have been described (50) . This includes the skipping of exon 4, exons 3 and 4, exons 2 and 3, and exon 9. The exon 3 skipping first observed in a gastrin-secreting islet cell tumor, and later in pancreatic ductal carcinomas and cholangiocarcinomas, has been reported to have no intrinsic activity and even to exhibit dominant negative activity to inhibit the function of wild type receptor (54) . This has the possible effect to reduce a growth inhibitor, thus stimulating neoplastic growth (50).
Specific Function in the Pancreas
The pancreatic effects of secretin are, indeed, the most extensively studied and best described (56) . This hormone was first recognized based on its ability to stimulate pancreatic exocrine secretion. Secretin receptors are present on pancreatic ductular cells, acinar cells, and even some cells within the islets (51, 57) . They are also present on a number of pre-neoplastic and neoplastic conditions, including panin lesions (pancreatic intraductal neoplasia), ductal adenocarcinomas, intraductal papillary mucinous tumor syndrome, serous cystic tumors, and some islet cell tumors (51) .
The major pancreatic function of secretin is to stimulate the secretion of bicarbonate, water, and electrolytes (34, 35, 56, 58, 59) . This is mediated by receptors present on the basolateral surface of ductular cells, where stimulation results in activation of cAMP and protein kinase A. This, in turn, activates cystic fibrosis transmembrane regulator to affect chloride flux, resulting in membrane depolarization. This increases the force of the electrogenic sodium-bicarbonate cotransporter that increases cytosolic bicarbonate and then secretes it at the apical membrane through the chloride/bicarbonate exchanger. As noted above, this effect is controlled by secretin secreted from intestinal S cells that are stimulated by intraluminal acidic chyme. The result of this alkaline secretion then neutralizes the acidic chyme, helping to establish an optimal milieu for the action of pancreatic and intestinal enzymes involved in the digestion of protein, lipid, and carbohydrate and their subsequent absorption. Of note, secretin also has a trophic effect on ductal cells, with biliary ductular proliferation observed upon stimulation with high concentrations of secretin; this is not seen with secretin administration to secretin receptor knockout mice (60) . Whether a similar effect occurs in the pancreas is unknown.
At the acinar cell, secretin stimulation can result in a modest secretion of zymogen content, including amylase, in some species (61) . It is noteworthy that this effect is weak in most species, with the rat acinar cell typical of this (48), and with the guinea pig acinar cell exhibiting a substantially greater response (49) . It has also been described that secretin can potentiate the exocrine secretory effect of cholecystokinin (62) . Secretin has also been described to modulate insulin and glucagon release from B and A cells within the islet (63-65).
Tools to Study the Secretin Receptor a. Molecular constructs
Mouse, rat, and human wild type secretin receptor cDNA clones in pDONR vector can be purchased from GeneCopoeia (www.genecopoeia.com). Human secretin receptor cDNA clone in pcDNA3.1 vector is available from UMR cDNA Resource Center, Missouri University of Science and Technology (www.cdna.org). Our laboratory uses rat and human secretin receptor cDNA clones in pcDNA 3.0. Additionally, a human secretin receptor splice variant missing exon 3 in pcDNA3.0 (54) and another variant missing both exon 3 and 4 in pBluescript KS+ vector (55) have been prepared in our laboratory.
b. Antibodies
Polyclonal anti-secretin receptor antibodies raised against the full-length receptor or its peptide fragments are commercially available from a number of vendors, including Abbiotec (250854), Abcam (ab85565 and ab58654), Abnova Corp. However, we have not tested any of these in our laboratory. We were able to insert a hemagglutinin (HA) tag in position 37 of the mature secretin receptor (66) and have used anti-HA antibody for immunostaining and Western blot studies. Dr. B. K. Chow used an antibody raised against a mouse secretin receptor fragment for immunofluorescence staining in his laboratory (40) . Additionally, two monoclonal antibodies directed against a secretin receptor splice variant missing both exons 3 and 4 have been generated in our laboratory (55) .
c. Transgenic mice
Secretin receptor knockout mice (SCTR -/-) have been developed in the laboratories of Dr. B. K. Chow (67) and Dr. I. Nishijima (68) . These SCTR -/-mice are described to be overtly normal and to be normally fertile.
However, upon focused evaluation, they have altered water reabsorption in the renal tubules due to reduced expression of urine concentration-regulating proteins, aquaporin 2 and 4, in the kidney (67) . They also have impaired synaptic plasticity in the hippocampus and slightly fewer dendritic spines in the CA1 hippocampal pyramidal cells, as well as exhibiting abnormal cognitive and social behaviors (68) .
d. Activity Binding
Affinity of the secretin receptor is determined by radioligand competition binding assay using a secretin radioligand and membranes prepared from cells expressing the secretin receptor (69) . Currently, there is not a commercial source of radiolabeled secretin for such assays. Oxidative labeling of natural secretin has been described, using strong oxidation for an extended time to incorporate the radioiodine into the histidine in position 1 (70) . However, this residue is critical for receptor binding and this radiolabel is not useful for receptor binding. Similarly, BoltonHunter reagent has been used to label the amino terminus of secretin (71) with the same negative effect on receptor binding. A simple oxidative radioiodination method is applicable to an analogue of secretin incorporating a tyrosine into position ten (72) . This technique is well described in that paper (72) .
Extensive photoaffinity labeling of the secretin receptor has also been performed (73) (74) (75) (76) (77) (78) . Sites of covalent attachment throughout the diffuse pharmacophore have been utilized, with many of these identifying residues within the receptor amino-terminal peptide-binding cleft (73) (74) (75) 78) , and with a few sites at the amino terminus of the secretin ligand labeling the receptor core helical budndle domain (76, 77) .
Techniques for photoaffinity labeling are reviewed in The Pancreapedia Research Tools page by Dong and Miller.
Ligand binding induces conformational changes in the receptor, leading to coupling preferentially to Gs to activate adenylate cyclase and to then increase intracellular cAMP. Therefore, the biological activity of the secretin receptor is determined by examining cAMP accumulation in cells expressing this receptor in response to ligand stimulation (75) . Any of the commercially available cAMP measurement kits are useful in this assay.
